

# Overactive Bladder Drug-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/O328096A4E5MEN.html>

Date: March 2018

Pages: 142

Price: US\$ 3,480.00 (Single User License)

ID: O328096A4E5MEN

## Abstracts

### Report Summary

Overactive Bladder Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Overactive Bladder Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Overactive Bladder Drug 2013-2017, and development forecast 2018-2023

Main market players of Overactive Bladder Drug in Europe, with company and product introduction, position in the Overactive Bladder Drug market

Market status and development trend of Overactive Bladder Drug by types and applications

Cost and profit status of Overactive Bladder Drug, and marketing status

Market growth drivers and challenges

The report segments the Europe Overactive Bladder Drug market as:

Europe Overactive Bladder Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Overactive Bladder Drug Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Others

Europe Overactive Bladder Drug Market: Application Segment Analysis (Consumption  
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

Europe Overactive Bladder Drug Market: Players Segment Analysis (Company and  
Product introduction, Overactive Bladder Drug Sales Volume, Revenue, Price and  
Gross Margin):

Astellas Pharma, Inc. (Japan)

Pfizer, Inc. (U.S.)

Teva Pharmaceutical Industries Limited (Israel)

Allergan, Plc (Ireland)

Medtronic plc (Ireland)

Mylan N.V. (U.S.)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Sanofi (France)

Apotex, Inc. (Canada)

Cogentix Medical, Inc. (U.S.)

Aurobindo Pharma Limited (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### CHAPTER 1 OVERVIEW OF OVERACTIVE BLADDER DRUG

- 1.1 Definition of Overactive Bladder Drug in This Report
- 1.2 Commercial Types of Overactive Bladder Drug
  - 1.2.1 Anticholinergics
  - 1.2.2 Solifenacin
  - 1.2.3 Oxybutynin
  - 1.2.4 Darifenacin
  - 1.2.5 Fesoterodine
  - 1.2.6 Tolterodine
  - 1.2.7 Trospium
  - 1.2.8 Others
- 1.3 Downstream Application of Overactive Bladder Drug
  - 1.3.1 Idiopathic Bladder Overactivity
  - 1.3.2 Neurogenic Bladder Overactivity
- 1.4 Development History of Overactive Bladder Drug
- 1.5 Market Status and Trend of Overactive Bladder Drug 2013-2023
  - 1.5.1 Europe Overactive Bladder Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Overactive Bladder Drug Market Status and Trend 2013-2023

### CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Overactive Bladder Drug in Europe 2013-2017
- 2.2 Consumption Market of Overactive Bladder Drug in Europe by Regions
  - 2.2.1 Consumption Volume of Overactive Bladder Drug in Europe by Regions
  - 2.2.2 Revenue of Overactive Bladder Drug in Europe by Regions
- 2.3 Market Analysis of Overactive Bladder Drug in Europe by Regions
  - 2.3.1 Market Analysis of Overactive Bladder Drug in Germany 2013-2017
  - 2.3.2 Market Analysis of Overactive Bladder Drug in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Overactive Bladder Drug in France 2013-2017
  - 2.3.4 Market Analysis of Overactive Bladder Drug in Italy 2013-2017
  - 2.3.5 Market Analysis of Overactive Bladder Drug in Spain 2013-2017
  - 2.3.6 Market Analysis of Overactive Bladder Drug in Benelux 2013-2017
  - 2.3.7 Market Analysis of Overactive Bladder Drug in Russia 2013-2017
- 2.4 Market Development Forecast of Overactive Bladder Drug in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Overactive Bladder Drug in Europe 2018-2023
  - 2.4.2 Market Development Forecast of Overactive Bladder Drug by Regions

2018-2023

## **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Overactive Bladder Drug in Europe by Types

3.1.2 Revenue of Overactive Bladder Drug in Europe by Types

### 3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

### 3.3 Market Forecast of Overactive Bladder Drug in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Overactive Bladder Drug in Europe by Downstream Industry

### 4.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Overactive Bladder Drug by Downstream Industry in Germany

4.2.2 Demand Volume of Overactive Bladder Drug by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Overactive Bladder Drug by Downstream Industry in France

4.2.4 Demand Volume of Overactive Bladder Drug by Downstream Industry in Italy

4.2.5 Demand Volume of Overactive Bladder Drug by Downstream Industry in Spain

4.2.6 Demand Volume of Overactive Bladder Drug by Downstream Industry in Benelux

4.2.7 Demand Volume of Overactive Bladder Drug by Downstream Industry in Russia

### 4.3 Market Forecast of Overactive Bladder Drug in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OVERACTIVE BLADDER DRUG**

### 5.1 Europe Economy Situation and Trend Overview

### 5.2 Overactive Bladder Drug Downstream Industry Situation and Trend Overview

## **CHAPTER 6 OVERACTIVE BLADDER DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

- 6.1 Sales Volume of Overactive Bladder Drug in Europe by Major Players
- 6.2 Revenue of Overactive Bladder Drug in Europe by Major Players
- 6.3 Basic Information of Overactive Bladder Drug by Major Players
  - 6.3.1 Headquarters Location and Established Time of Overactive Bladder Drug Major Players
  - 6.3.2 Employees and Revenue Level of Overactive Bladder Drug Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 OVERACTIVE BLADDER DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Astellas Pharma, Inc. (Japan)
  - 7.1.1 Company profile
  - 7.1.2 Representative Overactive Bladder Drug Product
  - 7.1.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Astellas Pharma, Inc. (Japan)
- 7.2 Pfizer, Inc. (U.S.)
  - 7.2.1 Company profile
  - 7.2.2 Representative Overactive Bladder Drug Product
  - 7.2.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Pfizer, Inc. (U.S.)
- 7.3 Teva Pharmaceutical Industries Limited (Israel)
  - 7.3.1 Company profile
  - 7.3.2 Representative Overactive Bladder Drug Product
  - 7.3.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Limited (Israel)
- 7.4 Allergan, Plc (Ireland)
  - 7.4.1 Company profile
  - 7.4.2 Representative Overactive Bladder Drug Product
  - 7.4.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Allergan, Plc (Ireland)
- 7.5 Medtronic plc (Ireland)

- 7.5.1 Company profile
- 7.5.2 Representative Overactive Bladder Drug Product
- 7.5.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Medtronic plc (Ireland)
- 7.6 Mylan N.V. (U.S.)
  - 7.6.1 Company profile
  - 7.6.2 Representative Overactive Bladder Drug Product
  - 7.6.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Mylan N.V. (U.S.)
- 7.7 Endo International plc (Ireland)
  - 7.7.1 Company profile
  - 7.7.2 Representative Overactive Bladder Drug Product
  - 7.7.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Endo International plc (Ireland)
- 7.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
  - 7.8.1 Company profile
  - 7.8.2 Representative Overactive Bladder Drug Product
  - 7.8.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Hisamitsu Pharmaceutical Co., Inc. (Japan)
- 7.9 Sanofi (France)
  - 7.9.1 Company profile
  - 7.9.2 Representative Overactive Bladder Drug Product
  - 7.9.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Sanofi (France)
- 7.10 Apotex, Inc. (Canada)
  - 7.10.1 Company profile
  - 7.10.2 Representative Overactive Bladder Drug Product
  - 7.10.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Apotex, Inc. (Canada)
- 7.11 Cogentix Medical, Inc. (U.S.)
  - 7.11.1 Company profile
  - 7.11.2 Representative Overactive Bladder Drug Product
  - 7.11.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Cogentix Medical, Inc. (U.S.)
- 7.12 Aurobindo Pharma Limited (India)
  - 7.12.1 Company profile
  - 7.12.2 Representative Overactive Bladder Drug Product
  - 7.12.3 Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of Aurobindo Pharma Limited (India)

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OVERACTIVE BLADDER DRUG**

- 8.1 Industry Chain of Overactive Bladder Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OVERACTIVE BLADDER DRUG**

- 9.1 Cost Structure Analysis of Overactive Bladder Drug
- 9.2 Raw Materials Cost Analysis of Overactive Bladder Drug
- 9.3 Labor Cost Analysis of Overactive Bladder Drug
- 9.4 Manufacturing Expenses Analysis of Overactive Bladder Drug

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF OVERACTIVE BLADDER DRUG**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources

12.2.2 Primary Sources  
12.3 Reference



## I would like to order

Product name: Overactive Bladder Drug-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/O328096A4E5MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O328096A4E5MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970